Ibrahim Aldoss, MD
Hematology · Duarte, CANPI 1861692485
Payments from drug & device makers
Across 1,465 payments — averaging $6773.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2.4M
- AbbVie$1.9M
- AstraZeneca$1.6M
- Macrogenics, Inc.$1.4M
- Janssen Research & Development, LLC$961K
- Takeda Pharmaceuticals U.S.A., Inc.$835K
- plus $738K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 28 | $2,441,953 |
| AbbVie | 114 | $1,925,789 |
| AstraZeneca(2 entities) | 21 | $1,632,788 |
| Macrogenics, Inc. | 1,127 | $1,389,192 |
| Janssen Research & Development, LLC | 39 | $960,828 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $834,875 |
| Jazz Pharmaceuticals Inc. | 25 | $343,562 |
| Novartis | 3 | $219,615 |
| Syndax Pharmaceuticals, Inc. | 17 | $95,447 |
| Gilead(2 entities) | 22 | $42,936 |
| Pfizer | 10 | $12,770 |
| Servier Pharmaceuticals LLC | 1 | $7,650 |
| Autolus Inc | 1 | $5,182 |
| Astrazeneca UK Limited | 1 | $4,920 |
| Adaptive Biotechnologies Corporation | 3 | $2,546 |
| Agios Pharmaceuticals, Inc. | 1 | $2,200 |
| Taiho Oncology, Inc. | 2 | $308 |
| Bristol Myers Squibb | 5 | $126 |
| Stemline Therapeutics Inc. | 1 | $97 |
| Genmab U.S., Inc. | 2 | $53 |
| Merck | 2 | $39 |
| Genentech USA, Inc. | 1 | $30 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $25 |
| Johnson & Johnson | 1 | $24 |
| Sanofi | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Seagen Inc. | 1 | $18 |
How this compares
$9,923,021 in reported general payments places this provider in the 90th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Duarte
- Alex HerreraDuarte$50.9M
- Tycel PhillipsDuarte$21.6M
- Lihua BuddeDuarte$21.5M
- Tanya SiddiqiDuarte$18.8M
- Amrita KrishnanDuarte$14M
- Anthony SteinDuarte$12.1M
- Alexey DanilovDuarte$11.3M
- Vincent ChungDuarte$11.1M
- Vinod PullarkatDuarte$10M
- Haris AliDuarte$7.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.